share_log

九洲药业(603456.SH):拟注销子公司瑞博生命科学和瑞博欧洲

Zhejiang Jiuzhou Pharmaceutical (603456.SH): plans to cancel its subsidiaries Ruibo Life Sciences and Ruibo Europe.

Gelonghui Finance ·  Jun 18, 2024 02:17

On June 18th, Gelonhui reported that Zhejiang Jiuzhou Pharmaceutical (603456.SH) plans to cancel its subsidiaries, Zhejiang Ruibo Life Science and Technology Co., Ltd. (referred to as "Ruibo Life Science") and Raybow Europe Incorporated ApS (referred to as "Ruibo Europe"), and authorize the management to handle the cancellation matters.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment